The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no prior anti–PD-1/PD-L1 treatment.
2025
Accelerated Approval Sought for RP1-Nivolumab Combo for Pretreated Melanoma
The FDA received a biologics license application for the accelerated approval of RP1 (vusolimogene oderparepvec) plus nivolumab (Opdivo) to treat adults with with advanced melanoma that was previously treated with a PD1 inhibitor.
Unexpected Findings in Study of T Cells, Considered Front-line Fighters Against Advanced Melanoma
Yale researchers made an unexpected discovery—turncoat T cells that help a tumor evade other cancer-fighting immune T cells—in a study of patients living with advanced melanoma that was published Nov. 28 in Nature Immunology.
Immune Cell Breakthrough: Scientists Discover a Hidden Ally in the Fight Against Cancer
Recent advances in immunotherapy research have revealed crucial roles for new immune cells in combating cancer, leading to potential strategies to enhance treatment efficacy and overcome resistance.